Simon Jules Nebel

Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations.

Quadia invests in companies located in Europe, South America, Asia and Africa. The firm targets companies operating in the fields of clean energy, sustainable food value chain and circular products & materials. They provide financing in the form of equity and debt for growth capital requirements.

Develops devices that integrate wearable sensor technology to be used in medical and rehabilitation field

Viopas Venture Consulting invests in companies located in Europe, primarily in Switzerland, Austria, and Germany. The firm focused on healthcare sectors includes digital health & medtech, pharma and biotech. It provides financing for pre-seed, early and late-stage capital requirements.

Operates as a clinical stage biopharmaceutical company

Develops antibody-drug conjugates

Zoeyplus invests in listed and private companies located across the DACH region. The firm target sectors includes biotech, medtech, healthcare and digital health companies. It provides financing for buyout transactions.